Agilent Technologies to increase pharmaceutical manufacturing capacity
US company aims to more than double its manufacturing capacity for nucleic acid active pharmaceutical ingredients
Agilent Technologies, which serves the life sciences, diagnostics and applied chemical markets, has acquired 20 acres in Weld County, Colorado, on which it plans to build a pharmaceutical manufacturing facility.
The expansion will enable the company to more than double its commercial manufacturing capacity for nucleic acid active pharmaceutical ingredients.
'The products manufactured at this site will be used by our customers to improve the lives of patients suffering from a variety of diseases,' said Skip Thune, general manager of the company's Nucleic Acids Solutions Division.
'At Agilent, we are committed to meeting the ever-increasing needs of our customers for oligonucleotides.'
Researchers believe oligonucleotides (short DNA and RNA molecules) hold the potential to treat various forms of cancer, diabetes, muscular dystrophy and other disorders.
Thune noted that the expansion would result in about 150 to 200 new, permanent jobs.
